DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D

First Posted Date: 2024-10-28

Last Posted Date: 2025-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT06661694

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: PF-06414300
Drug: Placebo

First Posted Date: 2024-10-26

Last Posted Date: 2024-10-26

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT06659250

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

ATTR-CM: A Multi-country, Non-interventional Disease Registry

Recruiting

Conditions: Transthyretin Amyloid Cardiopathy

First Posted Date: 2024-10-21

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 350

Registration Number: NCT06651073

Locations: 🇨🇳
National Taiwan University, Taipei City, Taiwan

Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy

Active, not recruiting

Conditions: Respiratory Syncytial Virus
Respiratory Tract Diseases

Interventions: Biological: ABRYSVO

First Posted Date: 2024-10-18

Last Posted Date: 2025-04-27

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06647654

Locations: 🇦🇷
Pfizer, Buenos Aires, Argentina

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ibuzatrelvir
Drug: carbamazepine ER

First Posted Date: 2024-10-17

Last Posted Date: 2025-02-03

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06646042

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: single dose of vepdegestrant as tablet formulation (Treatment A)
Drug: single dose of vepdegestrant as tablet formulation (Treatment B)

First Posted Date: 2024-10-17

Last Posted Date: 2025-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06645938

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Phase 3

Recruiting

Conditions: Menstrual Migraine

Interventions: Drug: Rimegepant
Drug: Placebo Comparator
Drug: Standard of Care

First Posted Date: 2024-10-15

Last Posted Date: 2025-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 723

Registration Number: NCT06641466

Locations: 🇯🇵
Tanaka Neurosurgery&Headache Clinic, Kagoshima, Japan
🇯🇵
Sendai Headache and Neurology Clinic, Sendai, Miyagi, Japan
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States

and more 21 locations

Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B

Not yet recruiting

Conditions: Hemophilia A
Hemophilia B

First Posted Date: 2024-10-10

Last Posted Date: 2025-03-05

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT06634836

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Phase 3

Recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: PF-06821497
Drug: Placebo
Drug: Enzalutamide

First Posted Date: 2024-10-08

Last Posted Date: 2025-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 900

Registration Number: NCT06629779

Locations: 🇺🇸
NextStage Clinical Research-Chicago-(04), Lisle, Illinois, United States
🇺🇸
Ironwood Cancer & Research Centers, Scottsdale, Arizona, United States
🇺🇸
Palo Verde Hematology Oncology, Glendale, Arizona, United States

and more 157 locations

A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia

Completed

Conditions: Breast Neoplasms

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 1128

Registration Number: NCT06624020

Locations: 🇦🇺
Pfizer Australia, Sydney, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy